FV100 as a new approach for the possible treatment of varicella-zoster virus infection.
FV100 is a promising new agent with extreme potency and specificity for varicella-zoster virus (VZV). It is the valyl ester pro-drug of Cf1743, the lead clinical candidate among the highly lipophilic bicyclic nucleoside analogue (BCNA) family discovered in Cardiff/Leuven. Cf1743 is unique amongst antivirals in terms of its structure and lipophilicity. It is exquisitely potent and selective for human VZV. FV100 has recently entered a randomized, controlled Phase II clinical trial for the treatment of shingles, sponsored by Inhibitex.
McGuigan
Christopher
C
Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff CF10 3NB, UK. mcguigan@cardiff.ac.uk
Balzarini
Jan
J
D000998:Antiviral Agents / Q000627:therapeutic use*; D018849:Controlled Clinical Trials as Topic; D006562:Herpes Zoster / Q000188:drug therapy*; D014645:Herpesvirus 3, Human / Q000187:drug effects*; D006801:Humans; D011741:Pyrimidine Nucleosides / Q000627:therapeutic use*
D000998:Antiviral Agents; C500967:Cf 1743; D011741:Pyrimidine Nucleosides